profit from every $100 of sales.
$0$100
Prime Medicine
$4.27+9.77% today
+20.3% in 1 year
1-year low $2.701-year high $5.36
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Prime Medicine sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $4.63 million in 2025, with -$201 million of profit last year.
SalesProfit
Prime Medicine vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Prime Medicine | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Prime Medicine's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 3 | 5 | |
| – | – | – | – | |
| -117 | -191 | -202 | -208 | |
| -114 | -187 | -196 | -201 | |
| -122 | -198 | -196 | -201 | |
| -4.19 | -2.18 | -1.65 | -1.35 | |
| – | – | – | – | |
| – | – | -6,787.4% | -4,498.1% | |
| – | – | -6,566.6% | -4,342.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 360 | 194 | 298 | 343 |
| Cash | 188 | 42 | 182 | 63 |
| Total debt | 29 | 14 | 41 | 116 |
| Total liabilities | 44 | 61 | 144 | 222 |
| 316 | 133 | 153 | 121 | |
| 34 | 91 | 119 | 149 | |
| -26.7% | -103.0% | -82.5% | -69.4% | |
| -38.5% | -148.9% | -127.9% | -166.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -132 | -165 | -123 | -163 | |
| 16 | 9 | 7 | 5 | |
| -148 | -174 | -130 | -167 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 6 | 14 | 26 | 29 |
Valuation
- –
- –
- –
- 7.5×
- 167.2×
- –
- –
- -21.6%
- -26.0%
- 0.0%
Profitability
- -1,082.7%
- -4,498.1%
- -4,342.4%
- -4,852.4%
- -77.4%
- -84.5%
- -188.8%
- -67.3%
- -79.9%
- 3,822.0%
Growth
- +55.3%
- –
- −28.4%
- –
- +11.6%
Financial health
- –
- 1.49
- 38.9%
- –
- 3.80
- 3.80
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Top 11%of 886
Bottom 4%of 987
What analysts expect
- Average price target
- $17.25
- Range
- $12.00 – $23.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.28 | -0.24 | −16.7% |
| Mar 3, 2026 | -0.22 | -0.25 | +12.0% |
| Nov 7, 2025 | -0.32 | -0.28 | −14.3% |
| Aug 7, 2025 | -0.41 | -0.36 | −13.9% |
| May 8, 2025 | -0.40 | -0.32 | −25.0% |
| Feb 28, 2025 | -0.31 | -0.37 | +16.2% |
| Nov 12, 2024 | -0.44 | -0.43 | −2.3% |
| Aug 8, 2024 | -0.46 | -0.40 | −15.0% |
News
An overlooked energy source could solve AI’s power crunch — and these 2 stocks are prime playsMarketWatch · Nov 3, 2026FCC to vote on auctioning 25MHz of 'prime spectrum' in move that could benefit Amazon, SpaceXCNBC · Oct 7, 2026Emmy Awards leave broadcast TV for Prime Video in 2027 under six-year dealCNBC · Oct 6, 2026Japan's prime minister says her policies will boost confidence in the yen after U.S. intervention falls shortCNBC · Oct 1, 2026Indian Prime Minister Modi says border peace is key to India-China tiesCNBC · Sep 12, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
19No pass
Benjamin Graham
30No pass
Philip Fisher
34No pass
Peter Lynch
80Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
43No pass
Questions about Prime Medicine
Is Prime Medicine a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Prime Medicine AI analysis
What does Prime Medicine do?
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It is in Biotechnology.
Does Prime Medicine pay a dividend?
No. Prime Medicine does not pay a dividend at the moment.
Is Prime Medicine stock halal?
Yes. Prime Medicine passes our halal screen: its business is permitted and its debt is 15% of its market value, under the 30% limit. How we check
How has Prime Medicine stock done over the past year?
Up 20.3% over the past twelve months, to $4.27. It traded between $2.70 and $5.36 and is 20.3% below its high.
Who are Prime Medicine's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Prime Medicine's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.